7-Year Alzheimer's watch: blood test may spot memory decline early

NCT ID NCT07142954

Recruiting now Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 4 times

Summary

This 7-year study follows 3,400 adults who report no memory problems but may be at risk for Alzheimer's. Researchers will use a blood test measuring P-tau217, a protein linked to Alzheimer's, to see if higher levels predict faster cognitive decline. The goal is to better understand how the disease progresses before symptoms appear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help identify early markers of Alzheimer's, leading to earlier detection and better monitoring of the disease.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly improve health. Results may take years and might not lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

Care Access - Houston
RECRUITING

Houston, Texas, 77054, United States
Higashi Shinjuku Clinic
RECRUITING

Tokyo, 169-0072, Japan
Souseikai Sumida Hospital
RECRUITING

Tokyo, 130-0004, Japan
The University of Tokyo Hospital
RECRUITING

Bunkyō City, 113-8654, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.